PTGS2 and neoplasm: Oral administration of HEGU decreased the expression of hypoxia-inducible factor-1α (HIF-1α) and the HIF-1α target genes inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) [24] in tumor tissues.